Barry Zingman, M.D.

Dr. Barry Zingman is Clinical Director of Infectious Diseases at the Moses Division of Montefiore Medical Center; Medical Director of the Montefiore AIDS Center; Professor of Medicine at Einstein; and Principal Investigator at Montefiore/Einstein of the NIH Adaptive COVID-19 Treatment Trial (ACTT) of remdesivir and other therapies for people hospitalized with severe COVID-19 infection.

Dr. Zingman’s interest in infectious diseases started when he was a medical student in the early 1980’s in New York City, caring for people newly diagnosed with an as-yet unnamed illness that was striking young men, drug users, and particularly people of color. This led him to specialize in internal medicine and infectious diseases, with a primary focus in care, teaching and research into HIV/AIDS. He has led dozens of studies of new therapies for HIV/AIDS over the last 30 years, chaired committees to improve care of people living with HIV/AIDS, and rose to directing the largest HIV program in New York State.

His involvement in COVID came as unexpectedly as it appeared, but his team, his colleagues and he took on the responsibility to try to offer hope to people stricken by the illness, their families, their providers and the world.  This research has led to the first therapy proven to work for COVID-19.